0001562884-21-000024.txt : 20210817 0001562884-21-000024.hdr.sgml : 20210817 20210817073849 ACCESSION NUMBER: 0001562884-21-000024 CONFORMED SUBMISSION TYPE: 8-K CONFIRMING COPY: PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210816 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20210817 DATE AS OF CHANGE: 20210817 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NUNZIA PHARMACEUTICAL Co CENTRAL INDEX KEY: 0000886093 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT SERVICES [8741] IRS NUMBER: 870442090 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39175 BUSINESS ADDRESS: STREET 1: 1627 WEST 14TH STREET CITY: LONG BEACH STATE: CA ZIP: 90813 BUSINESS PHONE: 714-609-9117 MAIL ADDRESS: STREET 1: 1627 WEST 14TH STREET CITY: LONG BEACH STATE: CA ZIP: 90813 FORMER COMPANY: FORMER CONFORMED NAME: Arizona Gold & Onyx Mining Co DATE OF NAME CHANGE: 20100730 FORMER COMPANY: FORMER CONFORMED NAME: VIKING CAPITAL GROUP INC DATE OF NAME CHANGE: 19931102 8-K 1 nunz-20210816.htm NUNZIA PHARMACEUTICAL COMPANY - FORM 8-K SEC FILING NUNZIA PHARMACEUTICAL COMPANY - Form 8-K SEC filing
0000886093 false 0000886093 2021-08-16 2021-08-16

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report: August 16, 2021

(Date of earliest event reported)

 

Commission File Number: 001-39175

 

NUNZIA PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)

 

 

Utah

(State or other jurisdiction of incorporation or organization)

87-0442090

(I.R.S. Employer Identification No.)

 

 

1627 West 14th Street, Long Beach, California

 

 

90813

(Address of principal executive offices)

(Zip Code)

 

(714) 609 9117

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

1

 

Section 1 - Registrant’s Business and Operations

Item 1.01 Entry into a Material Definitive Agreement.

 

On June 9, 2021 GoCloud through there JV Partnership with the suppliers and authorized distributor issued an email authorizing NUNZIA Pharmaceutical to sell the following vaccines: J&J, AZ, Pfizer, Moderna and Sputnick.

 

I have attached the email below.

2

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

NUNZIA PHARMACEUTICAL COMPANY

 

 

 

 

 

 

 

By: /s/ Michael Mitsunaga

 

Michael Mitsunaga

President

 

 

 

Dated: August 16, 2021

3

 

 

Exhibit

 

Umashankar Das <dr.udas999@gmail.com>

Jun 9, 2021, 3:41 PM

 

 

 

 

Hi Michael,

It was nice talking to you. As discussed with you we have good access to covid vaccines through our JV partnership with the supplier and authorized distributor. Gocloud will sell to Nunzia the following vaccines: J&J, AZ, Pfizer, Moderna and Sputnik. 

 

Please let us know your requirements. We look forward to working with you to fulfil your orders.

 

Thank you.

 

Dr. Umashankar Das, Ph.D., M.B.A.

President & CEO

Gocloud Technologies Inc.

4

 

 EX-101.DEF 2 nunz-20210816_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 3 nunz-20210816_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT City Area Code Entity Tax Identification Number Soliciting Material Entity File Number Details Pre-commencement Tender Offer Entity Registrant Name Document Type Entity Incorporation, State or Country Code Pre-commencement Issuer Tender Offer Local Phone Number Entity Address, State or Province Entity Address, City or Town Registrant CIK Document Period End Date Amendment Flag Entity Emerging Growth Company Entity Address, Address Line One Written Communications Entity Address, Postal Zip Code Fiscal Year End EX-101.PRE 4 nunz-20210816_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 5 nunz-20210816.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink XML 6 nunz-20210816_htm.xml IDEA: XBRL DOCUMENT 0000886093 2021-08-16 2021-08-16 0000886093 false 8-K 2021-08-16 001-39175 NUNZIA PHARMACEUTICAL COMPANY UT 87-0442090 1627 West 14th Street Long Beach CA 90813 (714) 609 9117 false false false false false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 16, 2021
Details  
Registrant CIK 0000886093
Document Type 8-K
Document Period End Date Aug. 16, 2021
Entity File Number 001-39175
Entity Registrant Name NUNZIA PHARMACEUTICAL COMPANY
Entity Incorporation, State or Country Code UT
Entity Tax Identification Number 87-0442090
Entity Address, Address Line One 1627 West 14th Street
Entity Address, City or Town Long Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90813
City Area Code (714)
Local Phone Number 609 9117
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports nunz-20210816.htm nunz-20210816.xsd nunz-20210816_def.xml nunz-20210816_lab.xml nunz-20210816_pre.xml http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nunz-20210816.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "nunz-20210816_def.xml" ] }, "inline": { "local": [ "nunz-20210816.htm" ] }, "labelLink": { "local": [ "nunz-20210816_lab.xml" ] }, "presentationLink": { "local": [ "nunz-20210816_pre.xml" ] }, "schema": { "local": [ "nunz-20210816.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 21, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "fil", "nsuri": "http://www.nunziapharma.com/20210816", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "nunz-20210816.htm", "contextRef": "D210816", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000010 - Document - Document and Entity Information", "role": "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "nunz-20210816.htm", "contextRef": "D210816", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Fiscal Year End" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Registrant CIK" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nunziapharma.com/20210816/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Details" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r3": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r4": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001562884-21-000024-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001562884-21-000024-xbrl.zip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end